KR870006016A - N-벤조일 우레아 화합물, 이를 함유하는 항종양 조성물 및 그의 제조 방법 - Google Patents

N-벤조일 우레아 화합물, 이를 함유하는 항종양 조성물 및 그의 제조 방법 Download PDF

Info

Publication number
KR870006016A
KR870006016A KR860010558A KR860010558A KR870006016A KR 870006016 A KR870006016 A KR 870006016A KR 860010558 A KR860010558 A KR 860010558A KR 860010558 A KR860010558 A KR 860010558A KR 870006016 A KR870006016 A KR 870006016A
Authority
KR
South Korea
Prior art keywords
group
compound
atom
hydrogen atom
substituted
Prior art date
Application number
KR860010558A
Other languages
English (en)
Inventor
다까히로 하기
노부또시 야마다
히데오 스기
도루 고야나기
히로시 오까다
Original Assignee
이시하라 겐조
이시하라상교 가부시끼 가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이시하라 겐조, 이시하라상교 가부시끼 가이샤 filed Critical 이시하라 겐조
Publication of KR870006016A publication Critical patent/KR870006016A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C07D213/643—2-Phenoxypyridines; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

내용 없음

Description

N-벤조일 우레아 화합물, 이를 함유하는 항종양 조성물 및 그의 제조 방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (15)

  1. 하기 일반식(I)의 N-벤조일 우레아 화합물.
    [상기 식중, X는 수소원자, 할로겐원자 또는 니트로기이며, n은 1-3의 정수이고, Q는
    (식중, Y1은 치환 또는 비치환알킬기, 또는 알킬부가 치환 또는 비치환된 알콕시 또는 알콕시 카르보닐기이며, Y2는 수소원자, 할로겐원자, 니트로기, 치환 또는 비치환 알킬기 또는 알킬부가 치환 또는 비치환된 알콕시 또는 알콕시카르보닐기이고, Z는 수소원자, 할로겐원자, 트리플루오로메틸기 또는 니트로기이며, A 및 B중의 하나는 =CH-이고 다른 하나는 질소원자라는 조건하에 A 및 B는 각각 =CH-또는 질소원자이다)이며, 단(1) Q가
    여기서 X가 수소원자이고, Y1이 알킬기일때, Z는 수소원자, 할로겐원자 또는 트리플루오로 메틸기가 아니며, (2) Q가
    (식중, A는 질소원자이고. Y1은 트리플루오로메틸기이다)일때, Y2는 수소원자 이외의 기이다].
  2. 제1항에 있어서, Q가
    인 N-벤조일 우레아 화합물.
  3. 제2항에 있어서, X가 질소원자 또는 할로겐원자이고, Y1이 할로겐으로 치환될 수 있는 알킬기이며, Y2가 수소원자이고, Z가 할로겐원자인 N-벤조일 우레아 화합물.
  4. 제1항에 있어서, Q가
    인 N-벤조일 우레아 화합물.
  5. 제4항에 있어서, Y2가 할로겐으로 치환될 수 있는 알킬기이고, A가 소원자이며, B가 =CH-이고, Z가 할로겐원자인 N-벤조일 우레아 화합물.
  6. 제2항에 있어서, N-(2-니트로벤조일)-N'-[4-(5-클로로-2-피리미디닐옥시)-3-메틸페닐]우레아인 화합물.
  7. 제2항에 있어서, N-(2-니트로벤조일)-N'-[4-(5-브로모-2-피리미디닐옥시)-3-메틸페닐]우레아인 화합물.
  8. 제4항에 있어서, N-(2-니트로벤조일)-N'-[3-(5-클로로-2-피리미디닐옥시)-4-메틸페닐]우레아인 화합물.
  9. 하기 일반식(II)의 화합물을 하기 일반식(III) 또는 (IV)의 화합물과 반응시킴을 특징으로 하는, 하기 일반식(I)의 N-벤조일 우레아 화합물의 제조 방법.
    [상기 식중, X는 수소원자, 할로겐원자 또는 니트로기 이며; n은 1-3의 정수이고; Q는
    (식중, Y1은 치환 또는 비치환 알킬기, 또는 알킬부가 치환 또는 비치환된 알콕시 또는 알콕 시카르보닐기이며, Y2는 수소원자, 할로겐원자, 니트로기, 치환 또는 비치환 알킬기 또는 알킬부가 치환 또는 비치환된 알콕시 또는 알콕시카 로보닐기이고, Z는 수소원자, 할로겐원자, 트리플루오로메틸기 또는 니트로기이며, A 및 B중의 하나는 =CH-이고 다른 하나는 질소원자라는 조건하에 A 및 B는 각각 =CH-또는 질소원자이다)이며, 단(1) Q가
    여기서 X가 수소원자이고, Y1이 알킬기일때, Z는 수소원자, 할로겐원자 또는 트리플루오로메틸기가 아니며, (2) Q가
    식중, A는 질소원자이고, Y1은 트리플루오로메틸기이다)일때, Y2는 수소원자 이외의 기이며; R1은 이소시아네이트기, 아미노기,
    이고 R2는
    (식중, Y1및 Y2는 상기에서 정의한 바와 같고, R3는 R1과는 상이한 아미노기 또는 이소시아네이트기이다)또는 할로겐 원자이며, 단 R1이
    일 때, R2는 할로겐원자 이고, R1이 이소시아네이트기 또는 아미노기 일때, R2는
    이다.]
  10. 제9항에 있어서,
    와 반응시키는 N-벤조일 우레아 화합물의 제조 방법.
  11. 제10항에 있어서, R1이 이소시아네이트기 또는 아미노기이고, R2가
    인 N-벤조일 우레아 화합물의 제조 방법.
  12. 제9항에 있어서,
    와 반응시키는 N-벤조일 우레아 화합물의 제조 방법.
  13. 제12항에 있어서, R1이 이소시아네이트기 또는 아미노기 이고, R2가
    인 N-벤조일 우레아 화합물의 제조 방법.
  14. 치료에 유효한량의 제1항에 정의된 N-벤조일 우레아 화합물 및 약학적으로 수용 가능한 보조제를 함유한 항종양 조성물.
  15. 치료에 유효한량의 제1항에 정의된 N-벤조일 우레아 화합물을 질병에 걸린 대상에 투여함을 특징으로 하는 암의 치료방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR860010558A 1985-12-11 1986-12-10 N-벤조일 우레아 화합물, 이를 함유하는 항종양 조성물 및 그의 제조 방법 KR870006016A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP27818085 1985-12-11
JP60-178180 1985-12-11
JP279884 1985-12-12
JP27988485 1985-12-12
JP280694 1985-12-13
JP60280694 1985-12-13

Publications (1)

Publication Number Publication Date
KR870006016A true KR870006016A (ko) 1987-07-08

Family

ID=27336532

Family Applications (1)

Application Number Title Priority Date Filing Date
KR860010558A KR870006016A (ko) 1985-12-11 1986-12-10 N-벤조일 우레아 화합물, 이를 함유하는 항종양 조성물 및 그의 제조 방법

Country Status (14)

Country Link
US (1) US4863924A (ko)
EP (1) EP0226104B1 (ko)
JP (1) JPH0745473B2 (ko)
KR (1) KR870006016A (ko)
AR (1) AR244667A1 (ko)
AT (1) ATE60760T1 (ko)
AU (1) AU594098B2 (ko)
DE (1) DE3677478D1 (ko)
DK (2) DK164054C (ko)
ES (1) ES2033675T3 (ko)
GR (1) GR3001905T3 (ko)
IL (1) IL80776A (ko)
NZ (1) NZ218440A (ko)
PL (1) PL151012B1 (ko)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ212208A (en) * 1984-06-15 1988-04-29 Ishihara Sangyo Kaisha N-benzoyl-n'-pyrimidinyloxyphenyl ureas and pharmaceutical compositions
JPS62185013A (ja) * 1986-02-08 1987-08-13 Green Cross Corp:The 易吸収性医薬組成物
ZA89135B (en) * 1988-01-11 1989-10-25 Duphar Int Res Method of treating hematologic diseases and pharmaceutical composition to be used therefor
US5166180A (en) * 1988-01-11 1992-11-24 Duphar International Research B.V. Method of treating hematologic diseases and pharmaceutical composition to be used therefor
JPH029855A (ja) * 1988-03-31 1990-01-12 Ishihara Sangyo Kaisha Ltd 置換ベンゼン誘導体、それらの製造方法及びそれらを含有する抗癌性組成物
US5202487A (en) * 1988-09-13 1993-04-13 L'oreal 2-substituted para-aminophenols and their use for dyeing keratinous fibres
FR2637282B1 (fr) * 1988-09-13 1990-12-07 Oreal Para-aminophenols 2-substitues et leur utilisation pour la teinture des fibres keratiniques
JPH02196719A (ja) * 1989-01-24 1990-08-03 Green Cross Corp:The 粉末状医薬組成物
NZ234551A (en) * 1989-07-28 1991-10-25 Ishihara Sangyo Kaisha Benzoylurea derivatives and antitumour compositions
US6344476B1 (en) * 1997-05-23 2002-02-05 Bayer Corporation Inhibition of p38 kinase activity by aryl ureas
US7329670B1 (en) 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
US20080300281A1 (en) * 1997-12-22 2008-12-04 Jacques Dumas Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
US20080269265A1 (en) * 1998-12-22 2008-10-30 Scott Miller Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas
RU2319693C9 (ru) 1999-01-13 2008-08-20 Байер Копэрейшн Производные мочевины (варианты), фармацевтическая композиция (варианты) и способ лечения заболевания, связанного с ростом раковых клеток (варианты)
JP2002534468A (ja) 1999-01-13 2002-10-15 バイエル コーポレイション ｐ３８キナーゼ阻害剤としてのω−カルボキシアリール置換ジフェニル尿素
US7928239B2 (en) 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
WO2000042012A1 (en) 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
US7235576B1 (en) 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7371763B2 (en) * 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
JPWO2003029199A1 (ja) * 2001-09-28 2005-01-13 武田薬品工業株式会社 ベンゼン誘導体、その製造法および用途
US20030232765A1 (en) * 2001-12-03 2003-12-18 Bayer Corporation Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
US20030216396A1 (en) * 2002-02-11 2003-11-20 Bayer Corporation Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors
WO2003068228A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
US20040023961A1 (en) * 2002-02-11 2004-02-05 Bayer Corporation Aryl ureas with raf kinase and angiogenisis inhibiting activity
AU2003209118A1 (en) 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Aryl ureas as kinase inhibitors
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
PT1636585E (pt) 2003-05-20 2008-03-27 Bayer Pharmaceuticals Corp Diarilureias com actividade inibidora de cinase
US8637553B2 (en) 2003-07-23 2014-01-28 Bayer Healthcare Llc Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
PE20051046A1 (es) * 2003-11-28 2006-01-11 Novartis Ag Derivados de diaril-urea en el tratamiento de enfermedades dependientes de la quinasa de proteina
JP5304241B2 (ja) 2005-03-07 2013-10-02 バイエル・ヘルスケア・エルエルシー 癌の処置用のオメガ−カルボキシアリール置換ジフェニルウレアを含む医薬組成物
JP6541667B2 (ja) 2014-01-16 2019-07-10 エフ エム シー コーポレーションＦｍｃ Ｃｏｒｐｏｒａｔｉｏｎ 除草剤としてのピリミジニルオキシベンゼン誘導体
EP3271350B1 (en) 2015-03-18 2022-05-25 FMC Corporation Substituted pyrimidinyloxy pyridine derivatives as herbicides
TWI713530B (zh) * 2015-06-05 2020-12-21 美商艾佛艾姆希公司 作為除草劑之嘧啶氧基苯衍生物
CA2990839A1 (en) 2015-07-13 2017-01-19 E.I. Du Pont De Nemours & Company Aryloxypyrimidinyl ethers as herbicides
WO2018204164A1 (en) 2017-05-02 2018-11-08 Fmc Corporation Pyrimidinyloxy benzo-fused compounds as herbicides

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5615272A (en) * 1979-07-17 1981-02-14 Ishihara Sangyo Kaisha Ltd N-benzoyl-n'-phenylurea compound, its preparation, and insecticide containing the same
CA1233822A (en) * 1982-12-30 1988-03-08 David T. Chou Pesticidal benzoyl ureas and process for preparation
NZ212208A (en) * 1984-06-15 1988-04-29 Ishihara Sangyo Kaisha N-benzoyl-n'-pyrimidinyloxyphenyl ureas and pharmaceutical compositions
JPS6133176A (ja) * 1984-07-24 1986-02-17 Ishihara Sangyo Kaisha Ltd Ｎ−ニトロベンゾイル−ｎ’−ピリダジニルオキシフエニルウレア系化合物、それらの製造方法及びそれらを含有する抗癌剤
JPS6193163A (ja) * 1984-10-12 1986-05-12 Ishihara Sangyo Kaisha Ltd Ｎ−ベンゾイル−ｎ′−フエニルウレア系化合物、それらの製造方法並びにそれらを含有する抗癌剤
US4727077A (en) * 1985-02-20 1988-02-23 Ishihara Sangyo Kaisha Ltd. Benzoyl urea compounds, process for their production, and antitumorous compositions containing them

Also Published As

Publication number Publication date
IL80776A0 (en) 1987-02-27
DK118391A (da) 1991-06-18
AU594098B2 (en) 1990-03-01
US4863924A (en) 1989-09-05
AR244667A1 (es) 1993-11-30
NZ218440A (en) 1989-06-28
DK596586D0 (da) 1986-12-11
DK596586A (da) 1987-06-12
DK118391D0 (da) 1991-06-18
JPH0745473B2 (ja) 1995-05-17
ES2033675T3 (es) 1993-04-01
DK164054B (da) 1992-05-04
AU6558186A (en) 1987-06-18
IL80776A (en) 1991-03-10
EP0226104A2 (en) 1987-06-24
GR3001905T3 (en) 1992-11-23
JPS6399056A (ja) 1988-04-30
EP0226104A3 (en) 1988-09-07
DE3677478D1 (de) 1991-03-14
DK164054C (da) 1992-09-28
EP0226104B1 (en) 1991-02-06
PL151012B1 (en) 1990-07-31
PL262901A1 (en) 1988-09-29
ATE60760T1 (de) 1991-02-15

Similar Documents

Publication Publication Date Title
KR870006016A (ko) N-벤조일 우레아 화합물, 이를 함유하는 항종양 조성물 및 그의 제조 방법
CA2012686A1 (en) Treatment and compounds
KR860007207A (ko) 페닐 카르바메이트 및 이것의 염을 제조하는 방법
JPS5356670A (en) N-benzoyl-n'-pyridyloxyphenyl urea compounds, process for preparation ofthe same, and insecticides containing the same as active constituents
RU92004433A (ru) Ароматические аминоспиртовые производные, способ их получения и фармацевтическая композиция
EP0194599A3 (en) Benzamide derivatives, process for producing the same, and soil fungicides containing the same
ES8503666A1 (es) Procedimiento para la preparacion de 1-ariloxi-2,3,4,5-tetrahidro-3-benzazepinas
KR850004585A (ko) 신규 아미노과니딘 유도체의 제조방법
KR930003908A (ko) 염증, 국소빈혈-유도된 세포의 손상 및 근디스트로피의 치료방법
KR890000417A (ko) 티오우레아 유도체
KR840006985A (ko) N-치환플라본-8-카르복사미드유도체 및 그 제조방법
KR910000647A (ko) 나프틸아미노-및 나프틸옥시- 피리딘아민 및 관련된 화합물, 이의 제조방법 및 이의 피부소염제로서의 용도
KR830004210A (ko) 2-아미노-3-벤조일-페닐아세트아미드 및 환상 동족체
HU903092D0 (en) Process for the preparation of buten-carboxylic acid derivatives and pharmaceutical compositions containing such compounds
KR830004217A (ko) 약학적 활성이 있는 펩타이드
EP0377966A3 (en) Novel benzopyranylpyrrolinone derivatives
EP0281412A3 (en) Novel organic platinum complex pharmaceutical compositions containing same and a process for the preparation thereof
CA2038025A1 (en) Optically active alkylenedioxybenzene derivatives and their use in therapy
JPS54112864A (en) Novel imidazole derivative, its mineral acid salt, and their preparation
KR940000443A (ko) 피리딜-1,2,5-옥사디아졸카복스아미드-2-옥사이드
RU93033697A (ru) Производные 2-амино-n-[[[4-(аминокарбонил) пиримидин-2-ил]амино] алкил] пиримидин-4-карбоксамида, способ их получения и фармацевтическая композиция на их основе
JPS56164122A (en) Drug composition comprising cimetidine as main agent
KR890009919A (ko) 4- 헤테로아릴-1,3- 벤조디아제핀 및 2-치환된-α-(헤테로아릴) 벤젠에탄아민, 이의 제조방법 및 약제로서의 이의 용도
JPS5412343A (en) N-(p-(substituted benzyloxy) phenyl)-n'-benzoylurea derivatives, their preparation, and insecticides and acaricides comprising them as active ingredients
IE33446L (en) Isothiocyano-diphenylamines

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application